Elicio Therapeutics Inc Asset Turnover Ratio (ELTX), as of third quarter 2026, current and historic results, rankings and more - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• Sales per Employee
• Income per Employee
• Inventory Turnover
• Asset Turnover
• Receivables Turnover
Elicio Therapeutics Inc   (NASDAQ: ELTX)
 

Elicio Therapeutics Inc Asset Turnover Ratio

Quarterly Results, Trends, Rankings, Statistics

Elicio Therapeutics Inc asset turnover ratio, the ability of Elicio Therapeutics Inc 's assets to generate revenue in the third quarter 2026, increased sequentially to 0.02 in the third quarter (Sep 30 2026), ELTX's balance sheet remain strong.

Within sector Elicio Therapeutics Inc achieved the highest asset turnover ratio. While asset turnover ranking remained unchanged in the Third Quarter 2026 compared to previous quarter at no. .

Asset Turnover Ratio Definition


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

ELTX Asset Turnover Ratio (Sep 30 2026)
III. Quarter		 (Jun 30 2026)
II. Quarter		 (Mar 31 2026)
I. Quarter		 (Dec 31 2025)
IV. Quarter		 (Sep 30 2025)
III. Quarter
Y / Y Asset Change 41.53 % 8.22 % -19.38 % 4.38 % -18.65 %
Y / Y Revenue Change - - - - -
Asset Turnover Ratio (TTM) 0.02 - - - -
ELTX's Total Ranking # # # # #
Seq. Asset Change 25.28 % 40.83 % -12.27 % -8.56 % -4.21 %
Seq. Revenue Change - - - - -



Asset Turnover Ratio Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall Market #

Asset Turnover Ratio Statistics
High Average Low
0 0 0
 




ELTX Company Profile • Back to ELTX Efficiency Comparisons • Compare ELTX Asset Turnover Ratio to its Competitors



Companies with similar Asset Turnover Ratio for the quarter ending Sep 30 2026, within Healthcare Sector Asset Turnover Ratio Revenues for 12 Months ending Sep 30 2026 Assets at quarter ending Sep 30 2026
Aclaris Therapeutics Inc   0.03 $ 6.401  Millions$ 188.758  Millions
Ideaya Biosciences Inc   0.03 $ 36.535  Millions$ 1,166.348  Millions
Prime Medicine Inc   0.03 $ 7.061  Millions$ 275.090  Millions
Medicinova Inc   0.02 $ 0.936  Millions$ 43.496  Millions
Vivosim Labs Inc   0.02 $ 0.135  Millions$ 7.029  Millions
Dbv Technologies S a   0.02 $ 3.844  Millions$ 234.675  Millions
Alumis inc   0.01 $ 7.239  Millions$ 533.214  Millions
Cardiff Oncology Inc   0.01 $ 0.559  Millions$ 46.200  Millions
Anteris Technologies Global Corp   0.01 $ 2.332  Millions$ 227.598  Millions
Crispr Therapeutics Ag  0.01 $ 25.172  Millions$ 2,549.561  Millions
Eyepoint Inc   0.01 $ 2.578  Millions$ 261.635  Millions
Upstream Bio Inc   0.01 $ 2.870  Millions$ 299.747  Millions
Absci Corp  0.01 $ 1.487  Millions$ 230.095  Millions
Prokidney Corp 0.00 $ 0.775  Millions$ 271.913  Millions



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.